Involvement of Na+ Transport and Natriuretic Hormones in the Antihypertensive Mechanism of Canrenone

  • P. Hannaert
  • M. De Mendqnca
  • M. L. Grichois
  • B. Thormann
  • J. P. Abitbol
  • R. Garay
Chapter
Part of the Developments in Nephrology book series (DINE, volume 18)

Abstract

A key step in the development of some forms of primary hypertension appears to be the disturbance in cell Na+ homeostasis induced by the interaction of endogenous “ouabain-like” factors (EOLF) with vascular cells having genetic abnormalities in membrane Na+ transport. Several arguments have suggested to us that Canrenone, an antihypertensive antialdosterone drug, may interfere with this mechanism (1). In vitro, this drug behaves like a partial agonist at the digitalis receptor site of the Na+, K+-pump (see for instance ref.1, 2): (i) under basal conditions, canrenone slightly inhibits Na+, K+-pump activity. An effect which can explain the previous observation that canrenone administration potentiates the inotropic effect of digitalis in dogs (3), (ii) canrenone is able to resti mulate a pump blocked by high doses of ouabain. This effect is likely correlated with its ability to protect against digitalis-induced cardiac toxicity (4) and to reverse the inhibitory effect of digoxin on basal and furosemide-stimulated renin secretion (5).

Keywords

Toxicity Catheter Glycoside Digoxin Renin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    GARAY, R.P., J. DIEZ, C. NAZARET, G. DAGHER and J.P. ABITBOL. 1985. Naunyn-Schmiedeberg’s Arch. Pharmacol. 329:311–315.CrossRefGoogle Scholar
  2. 2.
    FINOTTI, P. and P. PALATINI. 1981. J. Pharmacol. Exp.Ther. 217:784–790.PubMedGoogle Scholar
  3. 3.
    MARCHETTI, G., E. VITOLO, G.F. DIFRANCESCO, B. CAVALLARO and C. SPONZILLI. 1983. Arch. Int. Pharmacodyn. ther. 266:250–263.PubMedGoogle Scholar
  4. 4.
    YEH, B.K., B.N. CHIANG and P.K. SUNG. 1976. Am. Heart J. 92: 308–314.PubMedCrossRefGoogle Scholar
  5. 5.
    FINOTTI, P. and A. ANTONELLO. 1982. Clin. Pharmacol. Ther. 32: 1–6.PubMedCrossRefGoogle Scholar
  6. 6.
    MUGGE, A., W. SCHMITZ and H. SCHOLZZ. 1984. Klin. Wschr. 62: 717–723.PubMedCrossRefGoogle Scholar
  7. 7.
    HUOT, S.J., M.B. PAMNANI, D.L. CLOUGH and F.J. HADDY. 1983. Am. J. Nephrol. 3: 92–99.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1987

Authors and Affiliations

  • P. Hannaert
    • 1
  • M. De Mendqnca
    • 1
  • M. L. Grichois
    • 1
  • B. Thormann
    • 2
  • J. P. Abitbol
    • 2
  • R. Garay
    • 1
  1. 1.INSERM U7Hôpital NeckerParisFrance
  2. 2.Théraplix Lab.ParisFrance

Personalised recommendations